Scholarlink

<p>The evolution of precision medicine has propelled multimodal imaging-guided phototheranostics to the forefront for precise tumor diagnosis and therapy. Low-temperature photothermal therapy (PTT) offers a promising approach for the treatment of melanoma due to its non-invasiveness and minimal damage to normal tissues. However, its efficacy is limited by cancer cell thermal tolerance. To address this, a new type of multifunctional energy disruptor (CAMeO-Q NPs) is developed featuring homologous targeting and mitochondria targeting, and synergistically enhancing low-temperature PTT in melanoma by reversing heat shock protein 90 (Hsp90)-mediated thermal tolerance and blocking mitochondrial adenosine triphosphate (ATP) biosynthesis. The multifunctional energy disruptor enables precise trimodal imaging (fluorescence imaging/FLI, photoacoustic imaging/PAI, and photothermal imaging/PTI) guidance for low-temperature PTT. Comprising a mitochondria-targeting photothermal agent and an Hsp90 inhibitor, CAMeO-Q NPs induce selective mitochondrial damage under 660 nm laser irradiation and downregulate cellular HSP expression by ATP inhibition and Hsp90 inhibitor. This multifunctional energy disruptor provides a novel strategy for enhancing multimodal imaging-guided low-temperature photothermal therapy through combined homologous targeting, mitochondria-targeting, and Hsp90 inhibition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multifunctional mitochondria-targeting energy disruptor for enhancing imaging-guided low-temperature photothermal therapy of melanoma

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Shuo Li,
  • Yu-Qi Liu,
  • Guoyang Zhang,
  • Wentao Li,
  • Yutong Si,
  • Meng Liu,
  • Guo-Ling Zhang,
  • Zhuo Wang,
  • Ben Zhong Tang,
  • Hai-Tao Feng

摘要

The evolution of precision medicine has propelled multimodal imaging-guided phototheranostics to the forefront for precise tumor diagnosis and therapy. Low-temperature photothermal therapy (PTT) offers a promising approach for the treatment of melanoma due to its non-invasiveness and minimal damage to normal tissues. However, its efficacy is limited by cancer cell thermal tolerance. To address this, a new type of multifunctional energy disruptor (CAMeO-Q NPs) is developed featuring homologous targeting and mitochondria targeting, and synergistically enhancing low-temperature PTT in melanoma by reversing heat shock protein 90 (Hsp90)-mediated thermal tolerance and blocking mitochondrial adenosine triphosphate (ATP) biosynthesis. The multifunctional energy disruptor enables precise trimodal imaging (fluorescence imaging/FLI, photoacoustic imaging/PAI, and photothermal imaging/PTI) guidance for low-temperature PTT. Comprising a mitochondria-targeting photothermal agent and an Hsp90 inhibitor, CAMeO-Q NPs induce selective mitochondrial damage under 660 nm laser irradiation and downregulate cellular HSP expression by ATP inhibition and Hsp90 inhibitor. This multifunctional energy disruptor provides a novel strategy for enhancing multimodal imaging-guided low-temperature photothermal therapy through combined homologous targeting, mitochondria-targeting, and Hsp90 inhibition.